1 Exome copy number variant detection, analysis and classification in a large cohort of 2 families with undiagnosed rare genetic disease

3 4

5 6

Gabrielle Lemire,^{1,2,3,4,5,30,#} Alba Sanchis-Juan,^{1,2,4,5,30} Kathryn Russell,^{1,2} Samantha Baxter,^{1,2} Katherine R. Chao,^{1,2,5} Moriel Singer-Berk,^{1,2,5} Emily Groopman,^{1,2,3} Isaac Wong,^{2,5} Eleina England,^{1,2} Julia Goodrich,^{1,2,5} Lynn Pais,^{1,2,3,5} Christina Austin-Tse,^{1,2,5} Stephanie DiTroia,^{1,2,3,5} Emily O'Heir,^{1,2,5} Vijay S. Ganesh,^{1,2,3,4,5,6} Monica H. Wojcik,^{1,2,3,4} Emily Evangelista,^{1,2} Hana 7 Emily O'Heir, ^{Alio} Vijay S. Ganesh, ^{Alio} Monica H. Wojcik, ^{Alio, 1} Emily Evangelista, ¹² Hana Snow, ^{1,2} Ikeoluwa Osei-Owusu, ^{1,2,5} Jack Fu, ^{2,4,5} Mugdha Singh, ^{1,2,3,4,5} Yulia Mostovoy, ^{1,2,5} Steve Huang,² Kiran Garimella,² Samantha L. Kirkham,³ Jennifer E. Neil, ^{3,7} Diane D. Shao, ^{3,4,8} Christopher A. Walsh, ^{2,3,4,7} Emanuela Argili, ^{9,10} Carolyn Le, ^{9,10} Elliott H. Sherr, ^{9,10} Joseph Gleeson, ^{11,12} Shirlee Shril, ^{4,13} Ronen Schneider, ^{4,13} Friedhelm Hildebrandt, ^{4,13} Vijay G. Sankaran, ^{2,4,14} Jill A. Madden, ^{3,15} Casie A. Genetti, ^{3,15} Alan H. Beggs, ^{2,3,4,15} Pankaj B. Agrawal, ^{2,3,4,15} Kinga M. Bujakowska, ^{2,4,16} Emily Place, ^{2,4,16} Eric A. Pierce, ^{2,4,16} Sandra 8 9 10 11 12 13 Donkervoort,¹⁷ Carsten G. Bönnemann,¹⁷ Lyndon Gallacher,^{18,19} Zornitza Stark,^{18,19} Tiong Tan,^{18,19} Susan M. White,^{18,19} Ana Töpf,²⁰ Volker Straub,²⁰ Mark D. Fleming,^{4,21} Martin R. Pollak,^{4,22} Katrin Õunap,^{23,24} Sander Pajusalu,^{23,24} Kirsten A. Donald,^{25,26} Zandre Bruwer,^{25,26} Gianina Ravenscroft,²⁷ Nigel G. Laing,²⁷ Daniel G. MacArthur,^{1,2,28,29} Heidi L. Rehm,^{1,2,4,5} Michael E. Talkowski,^{1,2,4,5} Harrison Brand,^{1,2,4,5,31} Anne O'Donnell-Luria^{1,2,3,4,31,#} 14 15 16 17 18 19 20 ¹Broad Institute Center for Mendelian Genomics, Broad Institute of MIT and Harvard, 21 Cambridge, MA, USA ²Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, 22 23 MA, USA ³Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA 24 25 ⁴Harvard Medical School, Boston, MA, USA ⁵Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA 26 27 ⁶Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA 28 ⁷Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA, USA ⁸Department of Neurology, Boston Children's Hospital, Boston, MA, USA 29 ⁹Department of Neurology, University of California, San Francisco, San Francisco, CA, USA 30 31 ¹⁰Institute of Human Genetics and Weill Institute for Neurosciences, University of California, San 32 Francisco, San Francisco, CA, USA 33 ¹¹Department of Neurosciences, University of California San Diego, La Jolla, CA, USA ¹²Rady Children's Institute for Genomic Medicine, San Diego, CA, USA 34 35 ¹³Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA 36 ¹⁴Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA 37 ¹⁵The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, 38 39 USA 40 ¹⁶Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear 41 Infirmary, Boston, MA, USA ¹⁷Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, 42 43 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, 44 MD, USA ¹⁸Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia 45 ¹⁹Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria, 46 47 Australia ²⁰John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle 48 Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK 49 ²¹Department of Pathology, Boston Children's Hospital, Boston, MA, USA 50 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

- 51 ²²Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, USA
- ²³Department of Clinical Genetics, Genetics and Personalized Medicine Clinic, Tartu University
 Hospital, Tartu, Estonia
- ²⁴Department of Clinical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University
 of Tartu, Tartu, Estonia
- ²⁵Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital,
- 57 Cape Town, South Africa
- 58 ²⁶University of Cape Town, Cape Town, South Africa
- ²⁷University of Western Australia, Harry Perkins Institute of Medical Research, QEII Medical
- 60 Centre, Nedlands, Australia
- 61 ²⁸Centre for Population Genomics, Garvan Institute, Sydney, Australia
- 62 ²⁹Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia

- 63 ³⁰These authors contributed equally
- 64 ³¹Senior authors
- 65 #Correspondance: glemiret@broadinstitute.org, odonnell@broadinstitute.org

97 Abstract

98

99 Copy number variants (CNVs) are significant contributors to the pathogenicity of rare genetic 100 diseases and with new innovative methods can now reliably be identified from exome 101 sequencing. Challenges still remain in accurate classification of CNV pathogenicity. CNV calling 102 using GATK-gCNV was performed on exomes from a cohort of 6.633 families (15.759 103 individuals) with heterogeneous phenotypes and variable prior genetic testing collected at the 104 Broad Institute Center for Mendelian Genomics of the GREGoR consortium. Each family's CNV 105 data was analyzed using the seqr platform and candidate CNVs classified using the 2020 106 ACMG/ClinGen CNV interpretation standards. We developed additional evidence criteria to 107 address situations not covered by the current standards. The addition of CNV calling to exome 108 analysis identified causal CNVs for 173 families (2.6%). The estimated sizes of CNVs ranged 109 from 293 bp to 80 Mb with estimates that 44% would not have been detected by standard 110 chromosomal microarrays. The causal CNVs consisted of 141 deletions, 15 duplications, 4 111 suspected complex structural variants (SVs), 3 insertions and 10 complex SVs, the latter two 112 groups being identified by orthogonal validation methods. We interpreted 153 CNVs as likely 113 pathogenic/pathogenic and 20 CNVs as high interest variants of uncertain significance. Calling 114 CNVs from existing exome data increases the diagnostic yield for individuals undiagnosed after 115 standard testing approaches, providing a higher resolution alternative to arrays at a fraction of 116 the cost of genome sequencing. Our improvements to the classification approach advances the 117 systematic framework to assess the pathogenicity of CNVs.

- 118
- 119
- 120
- 121 122
- 123
- 120
- 124
- 125

126 INTRODUCTION

127 Copy number variants (CNVs) are imbalances of genomic material compared with the reference 128 genome resulting in the addition (duplications and insertions) or removal (deletions) of genomic 129 segments. They vary in size but are defined as variants of more than 50 bp.^{1,2} CNVs are significant contributors to rare genetic disease.^{3,4} Chromosomal microarrays (CMA) have been 130 131 the recommended first-line clinical test to investigate individuals with suspected rare genetic 132 diseases, especially for multiple congenital anomalies and intellectual disability disorders,^{5,6} 133 though practice is moving towards exome sequencing as a first-line test.⁷ Standard clinical 134 CMAs can only detect CNVs larger than 50-100 kilobases, so this low resolution precludes most 135 gene- and exon-level detection of CNVs. Due to technical challenges, CNVs have not 136 traditionally been identified by standard exome sequencing which typically focuses on single 137 nucleotides variants (SNVs) and indels.

Traditionally, exome-based CNV algorithms^{8–10} have relied on exome read depth to inform of 138 139 the underlying copy number at a given locus. However, many factors influence exome read 140 depth so detecting CNVs from exome data is difficult due to the non-uniform distribution of 141 captured reads secondary to biases introduced by PCR amplification, exome capture, and 142 mapping. These factors make it challenging to differentiate between a technical artifact and a bona fide CNV. The GATK-gCNV tool¹¹ uses a probabilistic framework to infer rare CNVs from 143 144 read depth data in the presence of these systematic biases. The performance of GATK-qCNV has been benchmarked with genome sequencing; it achieved 97% precision in detecting de 145 146 novo CNVs captured by genome sequencing in 99 children from families with autism spectrum 147 disorder and achieved more than 95% sensitivity for rare CNVs captured by genomes that span more than 4 exons, and more than 90% positive predictive value at all CNV sizes.¹¹ 148 149 We used the GATK-gCNV algorithm to call CNVs across the Broad Institute Center for

150 Mendelian Genomics (Broad CMG) exome cohort, a research center within the Genomics

151 Research to Elucidate the Genetics of Rare Diseases (GREGoR) consortium. The Broad CMG 152 has performed exome sequencing on more than 6,000 families with a suspected genetic 153 disease since 2016, representing a large cohort of individuals with heterogeneous phenotypes 154 including neurodevelopmental disorders, neuromuscular diseases, retinal disorders, blood 155 disorders, kidney diseases, multiple malformations syndromes, and other conditions. Most 156 individuals have had prior gene panels, exome, and/or clinical CMA but the level of prior genetic 157 testing is variable. Several molecular diagnostic laboratories and many research groups have 158 incorporated CNV calling in their exome analysis, particularly in recent years. The reported 159 additional diagnostic yield of CNV calling on exome data, most commonly used as a second-line 160 test after CMA, on various cohorts of patients with suspected rare genetic diseases varies 161 between 1 to 2%.^{12–16}

162 The widespread implementation of CMA and exome/genome sequencing is expanding the types 163 and numbers of CNVs identified in both clinical and research settings, and it can be challenging 164 to determine the impact of these CNVs on human health. Several resources have been or are 165 being developed to address this challenge. For instance, high quality reference population data such as gnomAD SV.¹⁷ a reference dataset of structural variants (SV) from short-read genome 166 167 sequencing of 10,847 individuals from the general population, helps determine the frequency of 168 a CNV in the population. Also, in silico prediction tools for CNVs are available including some 169 that have been developed with the goal of helping to distinguish deleterious CNVs from non-170 deleterious CNVs. For example, the StrVCTVRE score is a predictive tool that incorporates 171 gene importance, conservation, coding sequence, and exon structure of the disrupted region 172 and can evaluate CNVs overlapping coding sequences.¹⁸ CADD-SV, another example, is a tool 173 developed using machine-learning random forest models to differentiate deleterious from neutral SVs.¹⁹ 174

175 Importantly, accurate classification of CNV pathogenicity requires a consistent and transparent approach to be used across the human genetics field. Riggs et al. developed the American 176 177 College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource 178 (ClinGen) consensus standards to guide in the evaluation of germline CNVs and encourage consistency in CNV interpretation across laboratories, technologies and specialties.²⁰ They 179 180 proposed a quantitative evidence-based evaluation framework to classify copy number loss and 181 copy number gain that follow an autosomal dominant inheritance. These standards did not 182 intend to cover all curation scenarios and, for example, do not extend to guidance on how to 183 score CNVs following an autosomal recessive or X-linked inheritance, CNVs with available 184 functional evidence, or SVs beyond deletions and duplications. Here, we developed and applied 185 additional evidence criteria to address these limitations and assess the pathogenicity of all 186 CNVs that were thought to be causal in the Broad CMG exome cohort.

187

188 METHODS

189 Case selection

190 The Broad CMG was established in 2016 as part of an initiative funded by the National Human 191 Genome Research Institute of the National Institutes of Health, with the goal of discovering the 192 variants and genes underlying Mendelian disease to increase diagnosis rates for individuals with a suspected genetic condition.^{21–23} The Broad CMG is now part of the NHGRI Genomics 193 Research to Elucidate the Genetics of Rare diseases (GREGoR) consortium, the focus of which 194 195 includes evaluating different approaches to improve rare disease diagnosis, such as CNV 196 calling on exome data. Families recruited and sequenced through the Broad CMG are enrolled 197 in research studies with local institutional review board (IRB) approval, including for sharing de-198 identified samples for sequencing and analysis (MassGeneralBrigham 2013P001477).

Phenotypic information for the affected individuals in each family was provided using HPO
 terms.²⁴

201

202 From February 2016 to May 2021 (5 years, 3 months), 6,633 families underwent CNV calling on 203 exome data through the Broad CMG (15,759 individuals). This cohort had heterogeneous 204 phenotypes including neurodevelopmental, neuromuscular, multiple congenital anomalies, 205 hematological, ocular or renal disorders. Most were enrolled due to an unrevealing prior genetic 206 diagnostic evaluation as many had a CMA, gene panel sequencing for known causes of 207 disease, or clinical exome prior to research exome through the CMG. The sequenced 208 individuals were submitted from a large number of studies and had variable levels of pre-209 screening prior to enrollment (and this information was not systematically collected).

210 Exome sequencing

211 Exome sequencing was performed by the Genomics Platform at the Broad Institute of MIT and 212 Harvard. Libraries from DNA samples (>250 ng of DNA, at >2 ng/ul) were created with an 213 Illumina Nextera exome capture (37 Mb target) and sequenced (150 bp paired reads) to cover 214 >80% of targets at 20x and a mean target coverage of >80x from February 2016 through 215 January 2019 and then using a Twist exome capture (38 Mb target) and sequenced (150 bp 216 paired reads) to cover > 80% of targets at 20x and a mean target coverage of >60x thereafter. 217 Sample identity quality assurance checks were performed on each sample. The exome data 218 was de-multiplexed and each sample's sequence data were aggregated into a single Picard 219 CRAM file. The BWA aligner was used for mapping reads to the human genome build 38 220 (GRCh38). Single nucleotide variants and insertions/deletions (indels) were jointly called across 221 all samples using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 3.5. 222 Default filters were applied to SNV and indel calls using the GATK Variant Quality Score 223 Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor

(VEP), during upload of the callset to seqr²⁵ for collaborative analysis between the Broad CMG
 team and collaborating investigators.

226

227 CNV detection on exome data

228 CNVs were detected from exome sequencing following GATK-gCNV best practices¹¹, as

follows: read coverage was first calculated for each exome using GATK CollectReadCounts.

230 After coverage collection, all samples were subdivided into batches of a median of 410 samples

231 (range:160-625) for gCNV model training and execution; these batches were determined based

232 on a principal components analysis (PCA) of sequencing read counts. After batching, one gCNV

233 model was trained per batch using GATK GermlineCNVCaller on a subset of training samples,

and the trained model was then applied to call CNVs for each sample per batch. Finally, all raw

235 CNVs were aggregated across all batches and post-processed using quality- and frequency-

based filtering to produce the final CNV callset. Methods are further described in Babadi et al.¹¹

237

238 CNV analysis

239 Each family's CNV data was manually analyzed in coordination with the SNV/indel data by 240 members of the Broad CMG analysis team using our in-house developed analysis platform, 241 segr, an open-source, web-based tool for family-based monogenic disease analysis that 242 enables variant filtration, annotation and prioritization in addition to data sharing of candidate disease genes (with variants and HPO terms) through the Matchmaker Exchange.²⁵ CNVs were 243 244 filtered based on their mode of inheritance, gCNV quality scores (QS) (QS>50; developer 245 recommendations are QS>50 for duplications, >100 for deletions, and >400 for homozygous deletions, see Babadi *et al*¹¹ for details), and their frequency in the Broad CMG callset. For 246 247 autosomal dominant conditions, we filtered for CNVs with an allele frequency of <0.1% in the 248 Broad callset, and used <1% for autosomal recessive conditions. When analyzing each family, 249 factors used to help prioritize if a CNV was of clinical significance for a given individual included

the CNV size, its structural consequences (predicted loss-of-function (LoF) variant, copy gain),
its segregation pattern within the affected family, its frequency in the gnomAD-SV¹⁷ reference
population database, the number and characteristics of genes involved in the CNV, and *in silico*prediction of pathogenicity tools. Of note, the following criteria needed to be met for a SV in
gnomAD to be considered as the same allele:

either has sufficient reciprocal overlap (50% reciprocal overlap for large SV

- 255
- same SV type (duplication, deletion, etc)
- 256

257

>5Kb; 10% reciprocal overlap for SV <5Kb).

258 Genes included in a CNV were evaluated for gnomAD gene constraint scores, ClinGen dosage 259 sensitivity scores and disease association in OMIM; exons included in an intragenic CNV were evaluated for exon expression (pext score in gnomAD²⁶) and conservation. If no promising 260 261 variants were found using our initial searches, we removed the QS filter to include low-quality variants. We reviewed the StrVCTVRE score¹⁸ of candidate CNVs but did not use it to filter data 262 263 or rule out variants. The score ranges from 0-1, a score of 1 being more deleterious. In line with 264 the developer suggestions, CNVs with a score >0.37 were considered as having a higher 265 likelihood of being deleterious. To evaluate the guality of a given CNV, the patient's copy 266 number level was compared to any additional sequenced family members as well as a cluster of 267 other samples with similar read depth that act as controls. The copy number plot of each 268 compelling candidate was assessed to confirm an increase or decrease (corresponding to either 269 a gain or a loss) between the proband and the background cluster, and a difference in the 270 proband's copy number within versus outside the reported coordinates of the CNV (Figure 1). 271 We also visually inspected the read data of candidate CNVs using the Integrated Genomics 272 Viewer (IGV) to evaluate for sequencing artifacts (Figure 1).

- 273
- A CNV is defined as high-confidence by GATK-gCNV (see Babadi *et al.*¹¹ for details) if:

The CNV is present in a high-quality sample (with ≤ 200 autosomal raw CNV calls, of
 which at least 35 have QS >20)

- The sample frequency of the call is ≤ 0.01 within the Broad callset
- The number of overlapped exons is ≥ 3
- The QS score is equal or greater than the QS threshold (QS>50 for duplications, >100
- for deletions, and >400 for homozygous deletions)
- 281

282 CNV validation

283 CNV validations were performed by the investigator that contributed the sample by a variety of

284 methods (FISH, karyotype, CMA, MLPA, Sanger sequencing, quantitative PCR, droplet digital

285 (dd)PCR²⁷, genome sequencing) across different clinical or research laboratories, while some

were validated by short read or long read genome sequencing performed at the Broad

287 Genomics Platform (Table S1). Not all CNV identified by the gCNV pipeline were validated by

another method, largely when samples were from historic cohorts where there was not a path to

289 return results and often insufficient remaining DNA.

290

291 Evaluation of CMA coverage for each causal CNV

292 To evaluate how many causal CNVs could have been detected by a standard clinical CMA,

293 CNV detection sensitivity by CMA was assessed by evaluating the number of probes from the

Agilent GenetiSure Cyto CGH+SNP arrays (downloaded from https://genome.ucsc.edu/ on May

295 23, 2023) included within the genomic coordinates of a given CNV. A minimum number of five

probes was required to consider that the CNV would confidently be called by CMA²⁸.

297

298 Assessment of the pathogenicity of CNVs

299 We considered a case solved if the CNV was classified as pathogenic or likely pathogenic and

300 conclusively explained the phenotype or if a variant was found involving a novel disease gene

with moderate/strong supporting evidence by the ClinGen gene-disease validity criteria.²⁹ 301 Supporting genetic and/or experimental evidence were required to consider a CNV in a novel 302 303 gene as the diagnosis in a given family, most often by additional families identified through 304 Matchmaker Exchange. We also considered a case solved for cases where the analysis team 305 and referring provider, when relevant, considered the variant causative, even if a CNV was technically a variant of uncertain significance (VUS) by ACMG/ClinGen CNV criteria. 306 307 Each CNV was evaluated and classified by two curators (GL and KR). In order to systematically 308 assess the pathogenicity of the SVs in this study, the ACMG/ClinGen standards for interpretation and reporting of constitutional copy-number variants were applied.²⁰ For candidate 309 310 novel disease genes, the interpretation of gene-disease relationship was guided by the ClinGen 311 framework.²⁹ We developed an approach, including new curation criteria, to optimally capture 312 evidence for pathogenicity for the range of variants discussed in this article. 313 314 Determination of the number of protein-coding genes included in a CNV 315 In order to score points from section 3 from the Riggs standards ("evaluation of gene number"), 316 we used OMIM gene number count (https://genescout.omim.org/), and have compared it to the

317 gene number count provided by the DECIPHER browser (https://www.deciphergenomics.org/)

318 and the ClinGen browser (https://search.clinicalgenome.org/kb/gene-

- 319 <u>dosage?page=1&size=25&search=</u>).
- 320

321 Variants following autosomal recessive inheritance

322 The current ACMG/ClinGen CNV standards do not yet provide guidance on how to score CNVs

in genes for conditions that follow an autosomal recessive inheritance. To classify these variants

324 within this project, we developed an approach, advancing the current framework.

• We applied category 2E and the PVS1 LoF flowchart³⁰ for any intragenic CNV, or if a

326		CNV had a complete or partial overlap with a gene with an established gene-disease
327		relationship that follows an autosomal recessive inheritance.
328	٠	When the candidate CNV involved a gene with no established gene-disease
329		relationship, we did not score points from category 2, but rather used category 4 to build
330		up evidence for an established gene-disease relationship by finding additional cases
331		with overlapping variants from the literature.
332	٠	Points were awarded to the Broad CMG cases and published cases from the literature
333		using a similar system to that which is used when curating SNVs (the PM3 criteria)
334		[ClinGen Sequence Variant Interpretation Recommendation for in trans Criterion (PM3) -
335		Version 1.0 Working Group Page: https://clinicalgenome.org/working-groups/sequence-
336		variant-interpretation/, Approved: May 2, 2019]. The point-based system suggested in
337		the PM3 criteria was translated into points of similar strength level in the Riggs
338		quantitative framework ²⁰ (Table 1).
339	٠	We added 0.15 points when at least one individual with a unique phenotype (phenotype
340		is highly specific to disease, low genetic heterogeneity) has been reported by our study
341		or in the literature (equivalent of PP4 criteria in Richards et al ³¹)
342		a) In some cases, we awarded 0.30 points when evidence was particularly strong.
343		This only applied for genetic diseases with a specific, unique phenotype, high
344		clinical sensitivity testing (e.g. biochemical assays, enzyme deficiency assays,
345		functional cytogenetic tests (e.g. chromosomal breakage study)), and consistent
346		family history. These additional points were only used one time per variant.

347

325

348 Variants following X-linked inheritance

We developed the following flowchart to score points for CNVs with X-linked inheritance (Figure2).

351

352 Complex SVs

353 We defined a complex SV as a complex rearrangement typically composed of three or more breakpoint junctions that cannot be characterized as a single canonical SV type³². Some 354 355 complex SVs were suspected on exome CNV analysis and/or identified after further validation. As suggested by Riggs et al.²⁰, when classifying complex rearrangements (for example a paired 356 357 duplication inversion), we evaluated each CNV separately. The overall classification for the 358 event was defaulted to the most deleterious classification (for example, if the deletion portion 359 were classified as "pathogenic" and the duplication portion was classified as "uncertain 360 significance," the entire SV was classified as "pathogenic").

361

362 Inversions and Insertions

For variants initially called as deletion or duplication by GATK-gCNV in this cohort, some were identified as including inversions or insertions by validation methods. The Riggs *et al.*²⁰ standards do not provide guidance on how to score inversions or insertions. Therefore, we took guidance from Collins *et al.*³³ which states that inversions can be evaluated as a LoF event if exactly one breakpoint falls within a gene, or both breakpoints fall within the same gene and span at least one exon. Collins *et al.* also recommend evaluating a large insertion within an exon as a LoF event. We applied the LoF PVS1 criteria³⁰ as appropriate for such cases.

370

371 Variants with available functional evidence

372 We added an additional 0.15 points for any variant with at least supporting functional evidence

373 of pathogenicity, either from the investigation of our cases or from the literature. Examples

included: expression assays (Western blot for protein expression, PCR for RNA expression),

375 RNA sequencing, cellular assays (impaired localization and/or function) or protein interaction 376 studies. If the evidence was stronger, the points were upgraded to "moderate" (0.30 points) or 377 strong (0.45 points). For example, RNA sequencing results showing a clear and significantly 378 decreased expression of a gene or an animal model with the exact variant recapitulating the 379 disease phenotype was given 0.45 point (strong evidence).

380

381 RESULTS

382 CNV calling using the GATK-gCNV algorithm was performed on exomes from the Broad CMG 383 cohort of 6,633 families with heterogeneous rare disease phenotypes and variable prior genetic 384 testing that typically included a gene panel, exome, and/or CMA. A total number of 9,930 highconfidence (as defined in Babadi et al.¹¹) unique variants (4,387 deletions and 5,543 385 386 duplications) were identified across 15,759 individuals from these 6,633 families (Figure 3A and 387 Figure S1), 10.472 of the 15,759 samples had at least one rare (<1% frequency in the Broad 388 data callset) high-confidence CNV, and the median number identified was two (sd+-1.55) per 389 individual (Figure S1). The entire CNV callset for these individuals, with a total of 2,131,645 390 copy number calls (292,833 unique variants), was loaded into the segr platform for analysis. Many of these low-quality calls were likely artifacts, but by incorporating phenotype and allelic 391 392 variation (SNVs, indels, CNVs) in the analysis of each family, some low-quality CNV calls were 393 prioritized and ultimately interpreted as causal. Through the entire callset analysis, we have 394 identified a causal variant in 173 previously undiagnosed families. CNV calling on existing 395 exome data in this cohort thus resulted in an additional solve rate of 2.6% (173/6,633). The 396 causal CNVs consisted of 144 deletion, 15 duplication, and 14 suspected complex (multiple 397 CNVs on a chromosome) GATK-gCNV calls, which are currently resolved as 141 deletions, 15 398 duplications, 3 insertions, 10 complex SVs and 4 suspected complex SVs. Of the 10 validated 399 complex SVs, three were initially deletion or duplication calls where a complex SV was identified 400 on validation.

401

402	These CNVs mostly involved established genes/loci, but five families that are considered solved
403	had a CNV involving a novel disease gene candidate. Supporting genetic and/or experimental
404	evidence was required to consider a CNV in a novel gene as the explanation for a given family,
405	most often by additional families identified through Matchmaker Exchange ³⁴ or the literature.
406	The disorder followed an autosomal dominant inheritance in 93 families, an autosomal
407	recessive inheritance in 62 families and X-linked inheritance in 18 families (Figure 3B). The
408	CNV was confirmed de novo in 70/93 (75%) of the families with an autosomal dominant
409	disorder, inherited from a parent in 3/93 families (one inherited from an affected parent, one
410	involving an imprinted locus, and one inherited from an unaffected parent for a condition known
411	to harbor incomplete penetrance/variable expressivity) and the inheritance was unknown in
412	20/93 families. The CNV was confirmed <i>de novo</i> in 7/18 (39%) of the families with an X-linked
413	disorder. Detailed information on the CNV of each family is provided in Table S1. The
414	predominant phenotype present in the 173 families was neurodevelopmental disorders (54%)
415	followed by neuromuscular disorders (15%), but the cohort with causal CNVs also included
416	individuals with multiple congenital anomalies, hematological, ocular, and renal phenotypes.
417	The degree of prescreening before research exome differed between individuals from different
418	sub-cohorts and was therefore non-uniform across different phenotypes.
419	

The estimated sizes of causal CNVs by exome ranged from 293 bp to 80 Mb (Figure 3C). Twenty-two CNVs involved one exon and 14 CNVs involved two exons, which is below the benchmarked resolution of GATK-gCNV indicating it may be able to detect even smaller CNVs when allowing for a higher false positive rate. Large CNVs were also identified as some individuals did not have CMA prior to research enrollment. Large CNVs tend to be fragmented into multiple small GATK-gCNV calls. We interpreted fragmented CNVs as being part of a larger

426 CNV event in 35 families (35/173 (20%)) in this cohort after looking at the copy number plot427 and/or validation methods.

428

429 We sought to evaluate how many of the causal CNVs could have been detected by one of the 430 standard clinical CMAs, which is distinct from a high-density clinical array which often has one 431 or more probes per exon. Standard CMAs usually detect CNVs larger than 50-100 Kb but the 432 resolution varies across the genome and across different array designs as the probes are not 433 evenly spaced but are clustered around regions of clinical interest. CNV detection sensitivity by 434 a representative standard CMA was assessed based on the minimum number of probes 435 considered "sufficient" for CNV calling per target, which is defined as ≥ 5 probes for the Agilent GenetiSure Cyto array.²⁸ Based on this, we estimate that 44% (76/173) of these CNVs are 436 437 unlikely to have been detected by standard CMA.

438

439 More than half of the CNVs (105/173 (61%)) were validated by various orthogonal methods, 440 such as CMA, PCR, FISH, karyotype, MLPA, Sanger across the CNV or breakpoints, or short or 441 long read genome sequencing. Of note, some of these methods did not provide breakpoints but 442 rather only confirmed the copy number change. Of the 105 validated CNVs, 30 (29%) showed 443 differences when comparing the initial results with the orthogonal validation results: 19 showed 444 differences in gene/exon content and 11 showed differences in SV type. Importantly, the 445 difference in gene or exon content identified in 19 families did not result in a change in the 446 clinical interpretation of the CNV. Of note, only one of these 19 CNVs was curated as a VUS 447 and the difference in the number of exons included in the CNV did not change the scoring and 448 classification of this CNV. The 11 cases with different SV type consisted of eight complex SVs 449 which were either incompletely characterized or not suspected by GATK-gCNV on the exome, and a recurrent Alu insertion in the MAK gene (OMIM #614181)³⁵ identified in three individuals 450 451 with retinitis pigmentosa. This insertion was miscalled as a deletion by the GATK-qCNV

452 pipeline, but manual inspection of the exome reads showed discordant read pairs compatible453 with an Alu insertion. Sanger sequencing resolved the nature of this event.

454

455 Overall, there were 10 confirmed complex SVs in this cohort. We defined a complex SV as a 456 complex rearrangement typically composed of three or more breakpoint junctions that cannot be characterized as a single canonical SV type.³² A complex SV was suspected on the GATK-457 458 gCNV calls in 11 families (del/dup, paired dup, etc); seven of these were confirmed by genome, 459 aPCR or CMA (Table S1) and four remained unvalidated. Two deletions and one duplication 460 identified by GATK-gCNV in three different families were revealed to be complex SVs (paired deletion inversions and a paired inversion duplication) when validated by genome sequencing or 461 462 long-range PCR.

463

464 Twenty-four unrelated families with causal CNVs had a recurrent CNV that was identified in 465 more than one other unrelated family in this cohort. The recurrent 22q11.2 microdeletion 466 syndrome (OMIM #188400) was identified in nine individuals with neurodevelopmental disorders 467 in this cohort. Two individuals with a neurodevelopmental disorder were diagnosed with 22g13.3 468 deletion syndrome (Phelan-McDermid syndrome (OMIM #606232)). The 17q12 deletion 469 syndrome (OMIM #614527) was identified in two individuals with renal cystic disease. There 470 were multiple recurrent CNVs identified in the subgroup of individuals with retinal disorders in 471 this cohort. Indeed, four individuals of European ancestry affected with cone rod dystrophy had a heterozygous 1-exon-deletion in CLN3 (OMIM #204200) in trans with a pathogenic variant.³⁶ 472 473 A founder variant in the Ashkenazi Jewish population, an Alu insertion in MAK (OMIM #614181)^{35,37}, was found in three affected individuals of this ancestry. Two individuals of 474 475 different ancestries affected with retinitis pigmentosa were homozygous for the same 2-exondeletion in EYS (OMIM #602772), a deletion previously reported in the literature.^{36,38} Two 476 477 individuals of European ancestry affected with retinitis pigmentosa had a heterozygous 4-exon-

deletion in *EYS* (OMIM #602772), a deletion reported in multiple affected individuals in the
literature ^{36,39-41} in trans with a pathogenic or likely pathogenic variant. Detailed information on
the CNV of each of these families is provided in Table S1.

481

482 The StrVCTVRE in silico score was evaluated across the cohort. This score was viewable on 483 each CNV within segr during the initial analysis but was not used for filtering and not strongly 484 relied on in analysis (consistent with how other in silico scores are viewed in our analysis 485 pipeline). Sharo et al. reported that a 90% sensitivity is reached at a StrVCTVRE score of 0.37 486 (score ranges from 0-1, a score of 1 being more deleterious), which suggests that when used on 487 a collection of SVs called from a clinical cohort, this threshold may identify 90% of pathogenic SVs while reducing the candidate SV list by 54%.¹⁸ In this cohort, 161/168 unique causal CNVs 488 489 had a StrVCTVRE score greater than 0.37 (true positive rate of 0.96%), while this was the case 490 for 6162/10788 non-causal CNVs (false positive rate 0.57) (Table S2). The median score of the 491 161 unique causal CNVs was 0.77, and 0.42 for non-causal CNVs that had a StrVCTVRE score 492 calculated. One minor limitation of this analysis is that many large CNVs are fragmented, which 493 may result in lower StrVCTVRE scores for constituent parts than would be assigned for the 494 larger CNV event. While we manually reassembled and recalculated StrVCTVRE scores for 495 causal CNVs reported here (as it is appropriate to apply these scores to the entire CNV), non-496 causal CNVs were not reassembled. We note that all CNVs greater than 3Mb size automatically 497 had a score of 1 demonstrating a correlation between the CNV size and the StrVCTVRE score 498 (Figure S2).

499

500 Using the 2020 ACMG/ClinGen CNV interpretation standards²⁰ and additional evidence criteria 501 that we developed (detailed in the Methods section), we interpreted 153 CNVs as likely 502 pathogenic/pathogenic and 20 CNVs as VUS of high interest, including the 5 in novel disease-503 gene candidates (Figure 3C). When evaluating the pathogenicity of each CNV, we determined

- 504 the number of protein-coding genes included in each CNV and compared that number to three
- 505 different reference databases: OMIM (<u>https://genescout.omim.org/</u>), DECIPHER browser
- 506 (https://www.deciphergenomics.org/browser) and ClinGen browser
- 507 (https://search.clinicalgenome.org/kb/gene-dosage?page=1&size=25&search=) (Table S1). The
- vast majority of CNVs (148/173 (86%)) showed differences in gene number between these
- 509 three commonly used databases). Using the 2020 ACMG/ClinGen CNV interpretation
- 510 standards²⁰, different points are scored based on the number of genes included in a CNV
- 511 (section 3 of the standards). For example, 0 points are given for a deletion with 0-24 genes,
- 512 0.45 points for a deletion of 25-34 genes, and 0.9 points for a deletion of more than 35 genes.
- 513 For copy gain, 0 points are given for 0-34 genes, 0.45 points are given for 35-49 genes and 0.9
- points for more than 50 genes. We used the number of genes provided by the OMIM database
- 515 to perform the curation. Using the OMIM database versus DECIPHER resulted in a different
- 516 final score for 24/148 (16%) CNVs, but this would only alter the final classification for one CNV,
- as points were awarded from other sections. That altered case was a 857kb *de novo* 22q13
- 518 duplication which would be classified as a VUS if we use the gene number provided by OMIM
- 519 (28 protein-coding genes) but would be classified as pathogenic if we had used DECIPHER
- 520 browser (35 protein-coding genes). Detailed information on the CNV curation of each family is
- 521 provided in Table S1.
- 522

523 DISCUSSION

We present the analysis and curation results from CNV calling on exome data across a large and phenotypically heterogeneous cohort. The additional 2.6% solve rate of exome CNV calling identified in this cohort is comparable to previously reported diagnostic yield in other cohorts.^{12–} ¹⁶ In this cohort, most causal CNVs were deletions. Duplications were more common in the callset, but are less likely to disrupt gene function and also typically require more functional investigation to confirm a deleterious effect. Our callset contains many candidate duplications

530 (and deletions) that could potentially elucidate additional affected families, but their

531 pathogenicity remains uncertain and has not been further investigated.

532

533 Similar to using the probes on a microarray to estimate CNV size, the size of a CNV from 534 exome analysis is an estimate based on which exons have an abnormal copy number, but the 535 breakpoints typically occur somewhere within the introns. In addition, some exons have more 536 heterogeneous coverage and the deletion or duplication may involve more or fewer exons than 537 predicted. This can also result in a large CNV being called as multiple smaller events, but when 538 the data is reviewed, it can often be assembled into a larger event.

539

540 In this study, we did not attempt to validate and map all the CNV breakpoints, and we did not assess the validation rate of GATK-gCNV as this has been done previously.¹¹ A small number 541 542 of CNVs were nonetheless confirmed by genome sequencing by the Broad CMG as part of 543 initial efforts to validate gCNV performance. Of the 23 deletions and two duplications identified 544 by GATK-gCNV and validated by Broad CMG genomes, these were resolved as 22 deletions, 545 one duplication and two complex SVs. We recommended that any candidate CNV variants be 546 confirmed with an orthogonal method and generally validations are performed by the 547 collaborating researcher who recruited the individual for sequencing. The sensitivity of GATK-548 gCNV decays greatly for CNVs smaller than three exons (e.g. only ~50% for CNVs involving 1 exon), but the precision is relatively stable¹¹; interestingly, 36 CNVs (36/173 (21%)) in this 549 550 cohort involved fewer than 3 exons, highlighting the benefit of reviewing the full dataset with the 551 context of the patient's phenotype and for some cases, a pathogenic variant in trans, can 552 highlight small or poor quality CNV calls that warrant further attention. More than half of CNVs 553 were validated by various methods and validation is either underway or may not be possible for 554 the remainder of the identified CNVs. Importantly, the difference in size and in gene/exon 555 content for validated CNVs did not lead to a change in the interpretation of any of the CNVs

initially identified as causal, but it is possible that some interesting CNVs in this cohort wereoverlooked for that reason.

558

559 GATK-gCNV can only call deletions or duplications on exome data, so seven suspected 560 complex SVs and three initially unsuspected complex SVs in this cohort were identified by 561 orthogonal validation methods. We likely underdetected complex SVs as 39% of the CNVs in 562 this cohort were not validated and some validation methods would miss a more complex event, 563 such as droplet digital or quantitative PCR which only confirm the abnormal copy number 564 without mapping the breakpoints.

565 There are only a few *in silico* prediction tools available for CNV interpretation. Our group used 566 StrVCTVRE scores and we observed it was a useful tool to consider when prioritizing CNVs in 567 this cohort. Generally, we use in silico predictions as accessory annotations for review when 568 considering a variant rather than using it to filter out variants, even more so because large 569 CNVs may be represented by multiple smaller fragmented calls. More data on analysis of 570 cohorts of patients with rare diseases is needed to determine its utility overall and comparison to 571 other available SV predictors. Of note, StrVCTVRE only provides a prediction score for CNVs 572 overlapping a coding region, which was not a factor for this cohort given it was exome-based, 573 but this is a limitation of the score when considering genome sequencing and noncoding SVs.

High-quality reference population data is essential for effective CNV analysis. The gnomAD SV
database stands as a pivotal resource in human genetics but is currently limited to sequencing
data from short-read genomes. We used the database to evaluate if a given CNV was present
in the general population, which we found was useful for variant analysis and prioritization.

578 There are a myriad of technical differences between genome and exome sequencing and, while 579 studies have shown high overlap between CNV calling between the two techniques, the planned 580 addition of CNV calling on gnomAD exomes is anticipated to improve clinical CNV interpretation

since they will be more analogous from a technical standpoint. As the gnomAD SV dataset
expands in terms of size (incorporating both exome and genome data) and ancestral diversity,
its utility as an invaluable tool for both rare disease diagnosis and broader genetic studies will
only increase.

585 Standards for CNV classification are an important yet challenging area requiring ongoing 586 development. We proposed new evidence criteria to enable the assessment of the pathogenicity 587 of all CNVs that were thought to be causal in our cohort. We identified four areas that needed 588 additions or refinements. First, we suggested that functional data, including expression assays 589 (Western blot, PCR, RNA sequencing) and cellular assays (localization/function), be 590 incorporated as evidence at the supporting level of 0.15 points, and could be increased in 591 weight as appropriate. For example, abnormalities observed in RNA sequencing data or an 592 animal model with the same variant recapitulating the phenotype could be scored 0.3 or 0.45 593 points, respectively. Given the increasing availability of RNA sequencing, we suggest that 594 incorporating scoring for functional evidence is essential for CNV classification. Second, to 595 score CNVs involving genes associated with disorders with autosomal recessive inheritance, we 596 proposed an approach inspired by the ACMG/AMP criteria PM3 used for SNVs by incorporating 597 phase and classification of the second variant (Table 1). The point-based system suggested in 598 the PM3 criteria was translated into points of similar strength level in the Riggs quantitative framework. We also used the PVS1 flowchart³⁰ (or criteria 2E in Riggs et al.²⁰) for intragenic 599 600 CNVs or CNVs including at least one gene that had an established gene-disease relationship 601 following an autosomal recessive inheritance. Additional points were added based on 602 phenotype specificity and familial segregation. Third, to classify CNVs that follow an X-linked 603 inheritance pattern, we developed a scoring system based on biological sex of the proband, 604 parental genotype, and affected status of the transmitting parent (Figure 2). Points were 605 upgraded by one or two strength levels based on phenotype specificity. We also used the PVS1

flowchart³⁰ for intragenic CNVs or CNVs including at least one gene that had an established 606 gene-disease relationship following an X-linked inheritance. Finally, to evaluate SVs other than 607 deletion and duplication, we took guidance from Collins et al.³³, which states that LoF can be 608 609 expected if there is an insertion within an exon, if an inversion breakpoint falls within a gene, or 610 if both inversion breakpoints fall within the same gene and span at least one exon. We thus 611 applied the PVS1 LoF flowchart here. Our approach refined multiple aspects of CNV 612 classification and advanced the systematic framework to assess the pathogenicity of CNVs. 613 An important step in CNV classification involves determining the number of protein-coding

614 genes it contains. We observed some significant differences in gene number in CNVs evaluated 615 in this cohort depending on which database was queried, the OMIM database being the most 616 conservative. OMIM's gene count results from manual curation of published references, while 617 DECIPHER extracts this information directly from the Ensembl GRCh38 genome. OMIM might 618 thus underestimate the real number of genes present in a CNV and DECIPHER might 619 overestimate it. Even though different points were scored for several CNVs, the choice of which 620 database to use did not affect the final classification except for one duplication in this cohort. For 621 that duplication, the genes that were missing in OMIM but included in DECIPHER consisted of 622 seven protein-coding genes. Our group opted for a conservative approach and used the OMIM 623 database but this question needs to be further studied as this can lead to confusion during the 624 curation process. In addition, a sliding scale to score progressive points based on the increasing 625 number of genes in a given CNV could be used instead of fixed cutoffs, and features such as 626 loss of function constraint, haploinsufficiency, and triplosensitivity scores could be incorporated.

627 CONCLUSION

628 CNV calling and analysis from existing exome data increases the solve rate by 2.6% in this
629 diverse and presumed monogenic cohort. This is a higher resolution alternative to arrays at a
630 fraction of the cost of genome sequencing and can be applied retrospectively to existing exome

- datasets. We estimate that 44% of the 173 causal CNVs may not have been detected by
- 632 standard clinical CMAs. In classifying these variants, we advanced the current standards to take
- 633 into account additional types of evidence contributing to the systematic framework to assess the
- 634 pathogenicity of CNVs.
- 635

636 Data and code availability

- 637 The CNVs that were interpreted as causal in this cohort were submitted to ClinVar
- 638 (<u>https://www.ncbi.nlm.nih.gov/clinvar/</u>) (submitter ID 506627, Broad Rare Disease Group). The
- 639 ClinVar accession numbers of each CNV are listed in Table S1.
- 640

641 Acknowledgements

- 642 We thank the families who participated in this study for sharing their samples and medical data,
- along with all the research groups who collaborate with the Broad CMG. G.L. was supported by
- 644 the Fonds de recherche en santé du Québec (FRQS). A.S.J. was supported by a
- 645 Massachusetts General Hospital (MGH) Fund for Medical Discovery Research Award. V.S.G.
- 646 was supported by NIH NHGRI T32 (T32HG010464) and M.H.W. by NIH/NICHD K23HD102589.
- 647 Sequencing and analysis were provided by the Broad CMG, funded by the National Human
- 648 Genome Research Institute grants UM1HG008900, U01HG0011755 and R01HG009141. The
- 649 content is solely the responsibility of the authors and does not necessarily represent the official
- 650 views of the National Institutes of Health. Additional funding came from NIH/NINDS grants
- 651 R01NS032457, R01NS058721, NIH/NIDDK grant RC2DK122397, Sanofi Genzyme, Ultragenyx,
- 652 LGMD2I Research Fund, Samantha J. Brazzo Foundation, LGMD2D Foundation, Kurt+Peter
- 653 Foundation, Muscular Dystrophy UK, Coalition to Cure Calpain 3, European Union's Horizon
- 654 2020 research and innovation programme (grant agreement No. 779257 (Solve-RD)), the
- 655 Murdoch Children's Research Institute, the Harbig Foundation, the Victorian Government's
- 656 Operational Infrastructure Support Program, TUBITAK ((The Scientific and Technological

- 657 Research Council of Turkey) Project No. 216S771), and Estonian Research Council grants
- 658 PUT355, PRG471, PUTJD827, MOBTP175 and PSG774. We acknowledge the support
- 659 provided by Samantha G. Beck, Yasmine Chahine, R. Sean Hill and Abbe Lai for ddPCR
- 660 validation and variant interpretation. See supplemental for additional details.
- 661

662 **Declaration of interests**

- 663 H.L.R. has received support from Illumina and Microsoft to support rare disease gene discovery
- and diagnosis. A.O-D.L. has consulted for Tome Biosciences and Ono Pharma USA Inc. D.G.M
- 665 is a paid advisor to GlaxoSmithKline, Insitro, Variant Bio and Overtone Therapeutics, and has
- 666 received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Google, Merck,
- 667 Microsoft, Pfizer, and Sanofi-Genzyme. C.A.W. is a paid advisor to Maze Therapeutics. M.E.T.
- 668 receives research funding from Microsoft Inc, Illumina Inc and Levo Therapeutics. The
- 669 remaining authors declare no competing interests.
- 670

671 Web resources

- 672 seqr, <u>https://seqr.broadinstitute.org/</u>
- 673 GATK-gCNV, https://app.terra.bio/#workspaces/help-gatk/Germline-CNVs-GATK4
- 674 DECIPHER, https://www.deciphergenomics.org/
- 675 OMIM, <u>https://www.omim.org/</u>, <u>https://genescout.omim.org/</u>
- 676 ClinGen, <u>https://search.clinicalgenome.org/kb/gene-dosage?page=1&size=25&search=</u>
- 677 gnomAD, https://gnomad.broadinstitute.org/
- 678 ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/
- 679 MatchMaker Exchange, https://www.matchmakerexchange.org
- 680 StrVCTVRE, <u>https://strvctvre.berkeley.edu/</u>
- 681
- 682
- 683 684
- 685
- 686
- 607
- 687 688
- 689

690 REFERENCES

- Alkan, C., Coe, B.P., and Eichler, E.E. (2011). Genome structural variation discovery and genotyping. Nat. Rev. Genet. *12*, 363–376.
- 2. Zarrei, M., MacDonald, J.R., Merico, D., and Scherer, S.W. (2015). A copy number
 variation map of the human genome. Nat. Rev. Genet. *16*, 172–183.
- 3. Zhang, F., Gu, W., Hurles, M.E., and Lupski, J.R. (2009). Copy number variation in human
 health, disease, and evolution. Annu. Rev. Genomics Hum. Genet. *10*, 451–481.
- Weischenfeldt, J., Symmons, O., Spitz, F., and Korbel, J.O. (2013). Phenotypic impact of
 genomic structural variation: insights from and for human disease. Nat. Rev. Genet. *14*,
 125–138.
- Manning, M., Hudgins, L., and Professional Practice and Guidelines Committee (2010).
 Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. *12*, 742–745.
- Miller, D.T., Adam, M.P., Aradhya, S., Biesecker, L.G., Brothman, A.R., Carter, N.P.,
 Church, D.M., Crolla, J.A., Eichler, E.E., Epstein, C.J., et al. (2010). Consensus statement:
 chromosomal microarray is a first-tier clinical diagnostic test for individuals with
 developmental disabilities or congenital anomalies. Am. J. Hum. Genet. *86*, 749–764.
- 707 7. Manickam, K., McClain, M.R., Demmer, L.A., Biswas, S., Kearney, H.M., Malinowski, J.,
 708 Massingham, L.J., Miller, D., Yu, T.W., Hisama, F.M., et al. (2021). Exome and genome
 709 sequencing for pediatric patients with congenital anomalies or intellectual disability: an
 710 evidence-based clinical guideline of the American College of Medical Genetics and
 711 Genomics (ACMG). Genet. Med. *23*, 2029–2037.
- Fromer, M., Moran, J.L., Chambert, K., Banks, E., Bergen, S.E., Ruderfer, D.M.,
 Handsaker, R.E., McCarroll, S.A., O'Donovan, M.C., Owen, M.J., et al. (2012). Discovery
 and statistical genotyping of copy-number variation from whole-exome sequencing depth.
 Am. J. Hum. Genet. *91*, 597–607.
- Plagnol, V., Curtis, J., Epstein, M., Mok, K.Y., Stebbings, E., Grigoriadou, S., Wood, N.W.,
 Hambleton, S., Burns, S.O., Thrasher, A.J., et al. (2012). A robust model for read count
 data in exome sequencing experiments and implications for copy number variant calling.
 Bioinformatics *28*, 2747–2754.
- Krumm, N., Sudmant, P.H., Ko, A., O'Roak, B.J., Malig, M., Coe, B.P., NHLBI Exome
 Sequencing Project, Quinlan, A.R., Nickerson, D.A., and Eichler, E.E. (2012). Copy number
 variation detection and genotyping from exome sequence data. Genome Res. 22, 1525–
 1532.
- Babadi, M., Fu, J.M., Lee, S.K., Smirnov, A.N., Gauthier, L.D., Walker, M., Benjamin, D.I.,
 Zhao, X., Karczewski, K.J., Wong, I., et al. (2023). GATK-gCNV enables the discovery of
 rare copy number variants from exome sequencing data. Nat. Genet. 10.1038/s41588-02301449-0.
- Rajagopalan, R., Murrell, J.R., Luo, M., and Conlin, L.K. (2020). A highly sensitive and
 specific workflow for detecting rare copy-number variants from exome sequencing data.

- Genome Med. *12*, 14.
- Pfundt, R., Del Rosario, M., Vissers, L.E.L.M., Kwint, M.P., Janssen, I.M., de Leeuw, N.,
 Yntema, H.G., Nelen, M.R., Lugtenberg, D., Kamsteeg, E.-J., et al. (2017). Detection of
 clinically relevant copy-number variants by exome sequencing in a large cohort of genetic
 disorders. Genet. Med. *19*, 667–675.
- Marchuk, D.S., Crooks, K., Strande, N., Kaiser-Rogers, K., Milko, L.V., Brandt, A., Arreola,
 A., Tilley, C.R., Bizon, C., Vora, N.L., et al. (2018). Increasing the diagnostic yield of exome
 sequencing by copy number variant analysis. PLoS One *13*, e0209185.
- Bergant, G., Maver, A., Lovrecic, L., Čuturilo, G., Hodzic, A., and Peterlin, B. (2018).
 Comprehensive use of extended exome analysis improves diagnostic yield in rare disease: a retrospective survey in 1,059 cases. Genet. Med. 20, 303–312.
- Testard, Q., Vanhoye, X., Yauy, K., Naud, M.-E., Vieville, G., Rousseau, F., Dauriat, B.,
 Marquet, V., Bourthoumieu, S., Geneviève, D., et al. (2022). Exome sequencing as a firsttier test for copy number variant detection: retrospective evaluation and prospective
 screening in 2418 cases. J. Med. Genet. *59*, 1234–1240.
- 745 17. Collins, R.L., Brand, H., Karczewski, K.J., Zhao, X., Alföldi, J., Francioli, L.C., Khera, A.V.,
 746 Lowther, C., Gauthier, L.D., Wang, H., et al. (2020). A structural variation reference for
 747 medical and population genetics. Nature *581*, 444–451.
- Sharo, A.G., Hu, Z., Sunyaev, S.R., and Brenner, S.E. (2022). StrVCTVRE: A supervised
 learning method to predict the pathogenicity of human genome structural variants. Am. J.
 Hum. Genet. *109*, 195–209.
- 19. Kleinert, P., and Kircher, M. (2022). A framework to score the effects of structural variants
 in health and disease. Genome Res. *32*, 766–777.
- Riggs, E.R., Andersen, E.F., Cherry, A.M., Kantarci, S., Kearney, H., Patel, A., Raca, G.,
 Ritter, D.I., South, S.T., Thorland, E.C., et al. (2020). Technical standards for the
 interpretation and reporting of constitutional copy-number variants: a joint consensus
 recommendation of the American College of Medical Genetics and Genomics (ACMG) and
 the Clinical Genome Resource (ClinGen). Genet. Med. *22*, 245–257.
- Bamshad, M.J., Shendure, J.A., Valle, D., Hamosh, A., Lupski, J.R., Gibbs, R.A.,
 Boerwinkle, E., Lifton, R.P., Gerstein, M., Gunel, M., et al. (2012). The Centers for
 Mendelian Genomics: a new large-scale initiative to identify the genes underlying rare
 Mendelian conditions. Am. J. Med. Genet. A *158A*, 1523–1525.
- Posey, J.E., O'Donnell-Luria, A.H., Chong, J.X., Harel, T., Jhangiani, S.N., Coban Akdemir,
 Z.H., Buyske, S., Pehlivan, D., Carvalho, C.M.B., Baxter, S., et al. (2019). Insights into
 genetics, human biology and disease gleaned from family based genomic studies. Genet.
 Med. *21*, 798–812.
- Baxter, S.M., Posey, J.E., Lake, N.J., Sobreira, N., Chong, J.X., Buyske, S., Blue, E.E.,
 Chadwick, L.H., Coban-Akdemir, Z.H., Doheny, K.F., et al. (2022). Centers for Mendelian
 Genomics: A decade of facilitating gene discovery. Genet. Med. 24, 784–797.
- 769 24. Robinson, P.N., Köhler, S., Bauer, S., Seelow, D., Horn, D., and Mundlos, S. (2008). The

- Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease.
 Am. J. Hum. Genet. *83*, 610–615.
- Pais, L.S., Snow, H., Weisburd, B., Zhang, S., Baxter, S.M., DiTroia, S., O'Heir, E.,
 England, E., Chao, K.R., Lemire, G., et al. (2022). seqr: A web-based analysis and
 collaboration tool for rare disease genomics. Hum. Mutat. *43*, 698–707.
- Cummings, B.B., Karczewski, K.J., Kosmicki, J.A., Seaby, E.G., Watts, N.A., Singer-Berk,
 M., Mudge, J.M., Karjalainen, J., Satterstrom, F.K., O'Donnell-Luria, A.H., et al. (2020).
 Transcript expression-aware annotation improves rare variant interpretation. Nature *581*,
 452–458.
- Tai, A.C., Parfenov, M., and Gorham, J.M. (2018). Droplet Digital PCR with EvaGreen
 Assay: Confirmational Analysis of Structural Variants. Curr. Protoc. Hum. Genet. 97, e58.
- Pinto, D., Darvishi, K., Shi, X., Rajan, D., Rigler, D., Fitzgerald, T., Lionel, A.C.,
 Thiruvahindrapuram, B., Macdonald, J.R., Mills, R., et al. (2011). Comprehensive
 assessment of array-based platforms and calling algorithms for detection of copy number
 variants. Nat. Biotechnol. 29, 512–520.
- Strande, N.T., Riggs, E.R., Buchanan, A.H., Ceyhan-Birsoy, O., DiStefano, M., Dwight,
 S.S., Goldstein, J., Ghosh, R., Seifert, B.A., Sneddon, T.P., et al. (2017). Evaluating the
 Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed
 by the Clinical Genome Resource. Am. J. Hum. Genet. *100*, 895–906.
- 30. Abou Tayoun, A.N., Pesaran, T., DiStefano, M.T., Oza, A., Rehm, H.L., Biesecker, L.G.,
 Harrison, S.M., and ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI)
 (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant
 criterion. Hum. Mutat. *39*, 1517–1524.
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,
 M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of
 sequence variants: a joint consensus recommendation of the American College of Medical
 Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. *17*,
 405–424.
- Quinlan, A.R., and Hall, I.M. (2012). Characterizing complex structural variation in germline
 and somatic genomes. Trends Genet. 28, 43–53.
- 33. Collins, R.L., Brand, H., Redin, C.E., Hanscom, C., Antolik, C., Stone, M.R., Glessner, J.T.,
 Mason, T., Pregno, G., Dorrani, N., et al. (2017). Defining the diverse spectrum of
 inversions, complex structural variation, and chromothripsis in the morbid human genome.
 Genome Biol. *18*, 36.
- 804 34. Philippakis, A.A., Azzariti, D.R., Beltran, S., Brookes, A.J., Brownstein, C.A., Brudno, M.,
 805 Brunner, H.G., Buske, O.J., Carey, K., Doll, C., et al. (2015). The Matchmaker Exchange: a
 806 platform for rare disease gene discovery. Hum. Mutat. *36*, 915–921.
- 35. Tucker, B.A., Scheetz, T.E., Mullins, R.F., DeLuca, A.P., Hoffmann, J.M., Johnston, R.M.,
 Jacobson, S.G., Sheffield, V.C., and Stone, E.M. (2011). Exome sequencing and analysis
 of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated
 kinase (MAK) as a cause of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. *108*, E569–

- 811 E576.
- 36. Zampaglione, E., Maher, M., Place, E.M., Wagner, N.E., DiTroia, S., Chao, K.R., England,
 E., Cmg, B., Catomeris, A., Nassiri, S., et al. (2022). The importance of automation in
 genetic diagnosis: Lessons from analyzing an inherited retinal degeneration cohort with the
 Mendelian Analysis Toolkit (MATK). Genet. Med. *24*, 332–343.
- 816 37. Venturini, G., Koskiniemi-Kuendig, H., Harper, S., Berson, E.L., and Rivolta, C. (2015). Two
 817 specific mutations are prevalent causes of recessive retinitis pigmentosa in North American
 818 patients of Jewish ancestry. Genet. Med. *17*, 285–290.
- 819 38. Pieras, J.I., Barragán, I., Borrego, S., Audo, I., González-Del Pozo, M., Bernal, S., Baiget,
 820 M., Zeitz, C., Bhattacharya, S.S., and Antiñolo, G. (2011). Copy-number variations in EYS:
 821 a significant event in the appearance of arRP. Invest. Ophthalmol. Vis. Sci. *52*, 5625–5631.
- 822 39. Bujakowska, K.M., Fernandez-Godino, R., Place, E., Consugar, M., Navarro-Gomez, D.,
 823 White, J., Bedoukian, E.C., Zhu, X., Xie, H.M., Gai, X., et al. (2017). Copy-number variation
 824 is an important contributor to the genetic causality of inherited retinal degenerations. Genet.
 825 Med. *19*, 643–651.
- 826 40. Ellingford, J.M., Campbell, C., Barton, S., Bhaskar, S., Gupta, S., Taylor, R.L.,
 827 Sergouniotis, P.I., Horn, B., Lamb, J.A., Michaelides, M., et al. (2017). Validation of copy
 828 number variation analysis for next-generation sequencing diagnostics. Eur. J. Hum. Genet.
 829 25, 719–724.
- 41. McGuigan, D.B., Heon, E., Cideciyan, A.V., Ratnapriya, R., Lu, M., Sumaroka, A., Roman,
 A.J., Batmanabane, V., Garafalo, A.V., Stone, E.M., et al. (2017). EYS Mutations Causing
 Autosomal Recessive Retinitis Pigmentosa: Changes of Retinal Structure and Function with
 Disease Progression. Genes *8*. 10.3390/genes8070178.
- 834
- 835
- 836
- 837
- 838
- 839
- 840
- 841
- 842

- 844
- 845

846 **FIGURE LEGENDS**

869

847 Figure 1. Exome copy number plot and reads visualization for examples of causal CNVs 848 in the Broad CMG cohort. (A) Individual affected with retinitis pigmentosa with a homozygous 849 single exon deletion in *CRB1* (chr1:197438450-197439442x0, Quality score (QS) = 120) 850 identified on exome. To evaluate the quality of the CNV, the patient's copy number (CN) level 851 (in red) was compared to a cluster of other samples with similar read depth that act as controls. 852 The proband's CN is decreased compared to the background cluster, compatible with a 853 homozygous deletion. Y axis: CN. (B) As breakpoints fell within the exome data, manual 854 inspection of read data from the individual from (A) using the Integrated Genomics Viewer (IGV) 855 showed discordant read pairs, split reads and complete absence of coverage, compatible with a 856 homozygous exon 10 deletion also including part of upstream exon 9 in CRB1 857 (chr1:197435257-197441674x0 (NM_201253.3)). Cov= coverage. (C) Individual with multiple 858 congenital anomalies and a heterozygous deletion of 4 exons in RAB3GAP1 (Warburg micro 859 syndrome) (red, chr2:135162318-135164794x1, QS =92) in trans with a frameshift variant in 860 RAB3GAP1 (not shown, NM_012233.3: c.2393_2394del, p.Leu798ArgfsTer7), both identified by 861 exome. The presence of the deletion was validated by droplet digital PCR. Y axis: CN. (D) 862 Individual with a neurodevelopmental disorder with a *de novo* 2.6 Mb heterozygous 1q43q44 863 deletion (red, chr1:242523991-245156781x1, QS = 3077) identified on exome. The presence of 864 this deletion was validated by quantitative PCR. Y axis: CN. (E) Individual with a 865 neurodevelopmental disorder with a de novo 2.1Mb 22q11.2 duplication (red, chr22:18985739-866 21081116x3, QS = 3077) identified on exome. The presence of this duplication was validated by 867 chromosomal microarray. Y axis: CN. All coordinates on GRCh38. 868

870 **inheritance.** We incorporated sex of proband, parental genotype and parental affected status to

Figure 2. Flowchart illustrating how points were scored for CNVs that followed a X-linked

score both the proband in which the X-linked variant was identified and, if applicable, any
individual in the published literature or public databases that had variants of similar genomic
content to the variant of interest. The points for each case could be increased or decreased
based on phenotype specificity, up to 0.45 points.

875

876 Figure 3. Characteristics of CNVs across the entire callset and the subset of causal

877 **CNVs.** (A) Number of high-confidence CNVs by estimated size that were identified in the Broad 878 CMG exome callset of 6.633 families sequenced between 2016 and 2021. Large CNVs tend to 879 be fragmented into multiple small GATK-gCNV calls, accounting for why there are no CNVs in 880 the >10 Mb category of the graph. These CNVs were interpreted as being part of the same 881 underlying event when looking at the copy number plot and/or validation methods and are 882 presented that way in Figure 3B and 3C. DEL: deletion; DUP: duplication. (B) Mode of 883 inheritance and number of genes involved in each CNV in 173 families in which the CNV was 884 interpreted as causal. The number of genes included in each interval was chosen based on cutoffs suggested for CNV scoring in section 3 of the Riggs et al. ACMG/ClinGen standards.²⁰ 885 886 (C) CNV classification by estimated size in 173 families in which the CNV was interpreted as 887 causal by the multidisciplinary team. The causal CNVs consisted of 141 deletions, 15 888 duplications, 3 insertions (miscalled as deletion by GATK-gCNV), and 14 complex structural 889 variants (SV). We interpreted 153 CNVs as likely pathogenic/pathogenic and 20 CNVs as VUS. 890 891

- 892
- 893
- 894
- 895

Table 1. Adapted PM3 table to score CNVs in genes for conditions that follow an autosomalrecessive inheritance

Variant classification/zygosity	Points per Proband	
Variant classification/2ygosity	Confirmed in trans	Phase unknown
Second variant is pathogenic (P) or likely pathogenic (LP)	0.30	0.15 (P) 0.08 (LP)
Homozygous occurrence of this variant (max 0.30 point)	0.15	N/A
Second variant is a variant of uncertain significance (max 0.16 point)	0.08	0.0





Highly specific Pathogenic case evidence

The reported phenotype is highly specific and relatively unique to the gene or genomic region. Add 0.30 to the final score.

The reported phenotype is consistent with the gene/genomic region, is highly specific, but not necessarily unique to the gene/genomic region. Add 0.15 points to the final score.

The reported phenotype is consistent with the gene/genomic region, but not highly specific and/or with high genetic heterogeneity. Use the chart as is.

Nonspecific

Benign case evidence

The reported phenotype is consistent with the gene/genomic region, but not highly specific and/or with high genetic heterogeneity. Use the chart as is.

The reported phenotype is consistent with the gene/genomic region, is highly specific, but not necessarily unique to the gene/genomic region. Subtract 0.15 points from the final score.

The reported phenotype is highly specific and relatively unique to the gene or genomic region. Subtract 0.30 from the final score.

Highly specific

Nonspecific





